Future Outlook of Worldwide Ascites Market is Estimated to Reach USD 3710.4 Million By 2023 At A CAGR Of 4.0%

Ascites is an abnormal accumulation of fluid in the abdominal cavity. Liver cirrhosis is the most common case of ascites. Its presence is a sign of significant portal hypertension. Other less common factors that may contribute to ascites development are heart failure, kidney failure, cancers, and infection in the pancreas. Malignant ascites has a characteristic role in the progression of ovarian cancer. Malignancy-related ascites have also been observed in malignancies of breast, lung, pancreas, gastric, and liver. Ascites can be detected by physical examination at a volume greater than 1.5 ascites. For a smaller amount of fluid ultrasound and CT scan are preferred.

As ascites formation represents a hallmark in the history of chronic liver failure, and it predicts a poor outcome of 50% mortality rate within 3 years, adequate management of ascites and its complications would better quality of life and escalate the survival rate. Patients with mild ascites are advised to follow a low sodium intake diet to increase mobilization of the fluid retention. Diuretics are also a first-line treatment option for ascites. The most commonly recommended diuretics are spironolactone, furosemide, amiloride, metolazone, and mannitol. The second line treatment options for ascites includes discontinuation of beta blockers, serial therapeutic paracentesis, evaluation for liver transplantation, and TIPS. The third line treatment option includes peritoneovenous shunt. As there is not even a single pharmaceutical drug approved by FDA for the management of ascites. So, surgical interventions i.e. peritoneovenous shunting, liver transplantation, and transjugular intrahepatic portosystemic shunt (TIPS), also holds a strong share in the market.

However, various complications have been observed with ascites treatment approaches such as bleeding, small bowel perforation, stent placement complications, post-procedural complexities, and others. Some of these complications are rare and life-threatening. Thus, development of new drugs may emerge as the new revenue pockets for the growth of this market.

Get a Sample report at https://www.marketresearchfuture.com/sample_request/1909 .

Keen Players Bank on Novel Treatment Offering for Growth in Global Ascites Market

A number of players are operating in the global ascites market. Becton, Dickinson and Company (BD) has been recognized as a global leader with a broad range of products. BD develops and manufactures medical supplies, laboratory equipment, and diagnostic products worldwide. It operates through two segments worldwide i.e. BD Medical and BD Life Sciences. The product portfolio of company includes antibodies i.e. BD Pharmingen Ascites Mouse Anti-Ubiquitin, and BD Pharmingen Ascites Mouse Anti-PARP, and drainage products such as denver shunt, pleurX drainage system, and BD heimlich chest drain valve.

Medtronic is another well-established player in the ascites market. The company is the global leader in medical technology services. Medtronic Public Limited Company develops, manufactures and markets its medical devices to clinics & hospitals in approximately 160 countries. On January 26, 2015, Medtronic acquired Covidien plc for USD 42.9 Billion. The product portfolio of the company includes mainly Argyle Swan Neck Presternal Peritoneal Dialysis Catheter, Argyle Swan Neck Missouri Peritoneal Dialysis Catheter, Argyle Swan Neck Curl Cath Missouri Peritoneal Dialysis Catheter, Argyle Moncrief-Popovich Swan Neck Curl Cath Peritoneal Dialysis Catheter, and Argyle Peritoneal Dialysis Catheter Accessories, and turkel paracentesis procedure tray.

There are some pipeline drugs available for the management of ascites such as BIV201 by BioVie, Cell-in-a-Box capsule by PharmaCyte Biotech Inc., and others.

Improvement in Reimbursement Policies Stoking Growth of the Ascites Market

Ascites is one of the most common complications of cirrhosis, and it presents acute-on-chronic liver failure (ACLF). According to the data suggested by the Centres for Disease Control and Prevention in 2015, around 1.6% adults have been diagnosed with the chronic liver disease in the United States i.e. 3.9 million. It is also stated that from 2000 to 2015 death rates due to chronic liver disease and cirrhosis was increased by 31% in the United States among individuals aged 45–64 years.

The rising burden of ascites and related complications at an alarming rate are triggering various government or private associations to amend and improve their reimbursement policies. For instance, ALFApump System by Sequana Medical, a Switzerland based medical device company, has received approval from German Neue Untersuchungs und Behandlungsmethode (NUB), which allows hospitals to receive reimbursement for innovative new products. ALFApump System is a specially designed implantable pump system to treat ascites. The Medicare National Average Payment suggested by CMS for Peritoneal Drainage, used for the management of ascites, in 2017 is USD 1,453 in ambulatory surgery payment system and USD 2,862 for hospital outpatient payment system. The main aim of this support is lowering the mortality rate by ensuring proper post-operative procedures.

Get a discount at https://www.marketresearchfuture.com/check-discount/1909

The Americas dominate the ascites market owing to the well-developed technology, high healthcare expenditure, rising prevalence of cirrhosis, and the presence of the leading players. According to the data suggested by the Centres for Disease Control and Prevention in 2015, around 1.6 % adults have been diagnosed with the chronic liver disease in the U.S. i.e. 3.9 million. It is also stated that from 2000 to 2015 death rates due to the chronic liver disease and cirrhosis increased by 31% in the United States among individuals aged 45–64 years.

Europe holds the second position in the ascites market. It is expected that the support provided by the government bodies for research & development and the increase in a number of surgeries drives the market in European region. The liver is also very prevalent in European region. Owing to the increasing alcohol consumption and obesity, liver cirrhosis is the third most common cause of premature mortality in the UK as compared to other countries in Western Europe, suggested by a study published in BMJ Open in 2017

Asia Pacific region is projected to be the fastest growing region during the forecast period. Rapidly improving technology and the presence of huge patient pool is driving the growth of the market in this region.

The Middle East and Africa hold the least share of the ascites market owing to the presence of poor and slow developing countries, especially, in African region.

Access Report at https://www.marketresearchfuture.com/reports/ascites-market-1909 .

Notably, rising prevalence of cirrhosis is the key factors driving the ascites market. As per the study published in Hepatology journal in 2016, it is found that prevalence of the chronic liver disease is higher among Japanese Americans i.e. 6.9%. It is also stated that in whites, alcoholic liver disease was observed as the most common cause of cirrhosis i.e. 38.2%, whereas hepatitis C virus was most common in African Americans i.e. 29.8%

Improvement in reimbursement policies and increasing occurrence of cancer across the globe are also fuelling the market growth. According to a study published in the Cancer Biology & Medicine journal in 2017, it is found that ovarian cancer is the seventh most frequently diagnosed cancer among women in the world with an estimation of 239,000 new cases, and 152,000 deaths worldwide annually.

However, complications associated with ascites treatment may hinder the growth of the market over the forecast period. According to a study published in the Canadian Journal of Gastroenterology and Hepatology in 2016, serial large volume paracentesis (LVP) is considered as the first-line treatment for refractory ascites, and is also performed in an outpatient every 2 weeks. But there are certain complications associated with LVP such as bleeding, catheter fragmentation into the abdominal wall, and small bowel perforation.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

 Contact:
Market Research Future
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.